# US 2020/0400678 A1 · Modulator assay

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0400678 A1
- Document ID: US20200400678A1
- Status: Published application
- Kind: A1
- Application number: 16/883,859
- Filed: 2020-05-26
- Published: 2020-12-24
- Earliest claimed: 2015-06-18
- Assignees: Ucb Biopharma Srl
- Applicants: Ucb Biopharma Srl
- Inventors: James Philip O'CONNELL; John Robert PORTER; Alastair LAWSON; Boris KROEPLIEN; Stephen Edward RAPECKI; Timothy John NORMAN; Graham John WARRELLOW
- Web page: https://patentgrep.com/patent/US20200400678A1

## CPC

- G01N 33/6845: {Methods of identifying protein-protein interactions in protein mixtures}
- A61K 47/6425: {the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell}
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 213/72: Nitrogen atoms (nitro radicals C07D213/61)
- C07D 235/04: Benzimidazoles; Hydrogenated benzimidazoles
- C07D 239/26: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 401/14: containing three or more hetero rings
- C07D 471/00: Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D 471/04: Ortho-condensed systems
- C07K 14/525: Tumour necrosis factor [TNF]
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- C07K 16/241: {Tumor Necrosis Factors}
- G01N 33/6854: {Immunoglobulins}
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07K 2317/32: specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2333/525: Tumor necrosis factor [TNF]
- G01N 2333/7151: for tumor necrosis factor [TNF]; for lymphotoxin [LT]
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. A new assay for identifying compounds with this mechanism of action is also disclosed.

## Claims

### Claim 1

A method for identifying a compound that is capable of binding to a trimeric protein that is a tumor necrosis factor (TNF) superfamily member, whereby the compound-trimer complex binds to the requisite TNF superfamily receptor and modulates the signalling of the receptor, comprising:
a) identifying the binding of the compound to the trimeric form of the TNF superfamily member in a sample; and/or
b) measuring the stability of the trimeric form of the TNF superfamily member in a sample comprising the compound; and/or
c) measuring the level of trimeric TNF superfamily member bound to the requisite receptor in a sample comprising the compound; and/or
d) measuring the competition of the compound with a probe compound for binding to the trimeric form of the TNF superfamily member;
and comparing the binding of the compound to the trimeric form of the TNF superfamily member in (a), and/or the stability of the trimeric form of the TNF superfamily member in (b), and/or the level of trimeric TNF superfamily member bound to the requisite receptor in (c), and/or the level of competition observed in (d) to corresponding values from control samples and selecting a compound that is capable of binding to a trimeric protein that is a TNF superfamily member, whereby the compound-trimer complex binds to the requisite TNF superfamily receptor and modulates the signalling of the receptor.

### Claim 2 (depends on 1)

The method of claim 1, which comprises:
a) conducting a mass spectrometric analysis on a sample containing the TNF superfamily member and the compound to detect the amount of the TNF superfamily member trimer;
b) comparing the amount of TNF superfamily member trimer in the sample with a control sample; and
c) selecting a compound that is capable of binding to a trimeric protein that is a TNF superfamily member, whereby the compound-trimer complex binds to the requisite TNF superfamily receptor and modulates the signalling of the receptor.

### Claim 3 (depends on 1)

The method of claim 1, which comprises:
a) performing a receptor-ligand binding assay in which a sample of TNF superfamily member and the compound is applied to the requisite TNF receptor that has been bound to a surface;
b) comparing the amount of TNF superfamily member trimer bound to the requisite TNF receptor with a control sample; and
c) selecting a compound that is capable of binding to a trimeric protein that is a TNF superfamily member, whereby the compound-trimer complex binds to the requisite TNF superfamily receptor and modulates the signalling of the receptor.

### Claim 4 (depends on 1)

The method of claim 1, which comprises:
a) performing an assay to determine the thermal transition midpoint (Tm) of the trimeric form of the TNF superfamily member in a sample of the TNF superfamily member and the compound;
b) comparing the Tm of the trimeric form of the TNF superfamily member in the sample with a control sample; and
c) selecting a compound that is capable of binding to a trimeric protein that is a TNF superfamily member, whereby the compound-trimer complex binds to the requisite TNF superfamily receptor and modulates the signalling of the receptor.

### Claim 5 (depends on 1)

The method of claim 1, which comprises:
a) performing a fluorescence polarization assay using the compound and a probe compound;
b) comparing the degree of polarization of the probe compound in the presence of the compound with the degree of polarization in a control sample; and
c) selecting a compound that is capable of binding to a trimeric protein that is a TNF superfamily member, whereby the compound-trimer complex binds to the requisite TNF superfamily receptor and modulates the signalling of the receptor.

### Claim 6 (depends on 1)

The method of claim 1, wherein the sample containing the TNF superfamily member and the compound further comprises a destabilising agent.

### Claim 7 (depends on 6)

The method of claim 6, wherein the destabilising agent is dimethyl sulfoxide (DMSO).

### Claim 8 (depends on 1)

The method of claim 1, which comprises:
a) performing an isothermal calorimetric analysis to measure the binding of the TNF superfamily member for the requisite receptor in the presence of the compound;
b) comparing the binding of the TNF superfamily member for the requisite receptor with a control sample; and
c) selecting a compound that is capable of binding to a trimeric protein that is a TNF superfamily member, whereby the compound-trimer complex binds to the requisite TNF superfamily receptor and modulates the signalling of the receptor.

### Claim 9 (depends on 1)

The method of claim 1, wherein step (c) comprises measuring the binding affinity of trimeric TNF superfamily member to the requisite receptor in a sample comprising the compound.

### Claim 10 (depends on 1)

The method of claim 1, which comprises:
a) performing an assay to determine the binding affinity for a superfamily receptor (KD-r) of the trimeric form of the TNF superfamily member in a sample of the TNF superfamily member and the compound;
b) comparing the KD-r of the trimeric form of the TNF superfamily member in the sample with a control sample; and
c) selecting a compound that is capable of binding to a trimeric protein that is a TNF superfamily member, whereby the compound-trimer complex binds to the requisite TNF superfamily receptor and modulates the signalling of the receptor.

### Claim 11 (depends on 1)

The method of claim 1, wherein the compound increases the stability of the trimeric form of the TNF superfamily member compared to the stability of the trimeric form of the TNF superfamily member in the absence of the compound.

### Claim 12 (depends on 11)

The method of claim 11, wherein the increase in stability results in an increase in the thermal transition midpoint (Tm) of the trimeric form of the TNF superfamily member of at least 1° C.

### Claim at position 13

13-14. (canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein the compound increases the binding affinity of the TNF superfamily member to the requisite receptor compared to the binding affinity of the TNF superfamily member to its receptor in the absence of the compound.

### Claim 16 (depends on 15)

The method of claim 15, wherein the compound increases the binding affinity of the TNF superfamily member to the requisite receptor by increasing the on rate (kon-r) and/or decreasing the off rate (koff-r) compared to the kon-r and koff-r values for binding of the TNF superfamily member to its receptor in the absence of the compound.

### Claim 17 (depends on 15)

The method of claim 15, wherein the compound increases the binding affinity of the TNF superfamily member to the requisite receptor by increasing the on rate (kon-r) compared to the kon-r value for binding of the TNF superfamily member to its receptor in the absence of the compound.

### Claim 18 (depends on 15)

The method of claim 15, wherein the compound decreases the KD-r of the TNF superfamily member to the requisite receptor compared to the KD-r of the TNF superfamily member to its receptor in the absence of the compound, wherein:
a) the compound decreases the KD-r of the TNF superfamily member to the requisite receptor by at least 10 times compared to the KD-r of the TNF superfamily member to its receptor in the absence of the compound;
b) the KD-r value of the TNF superfamily member for binding to the requisite receptor in the presence of the compound is less than 10 nM.

### Claim 19 (depends on 15)

The method of claim 15, wherein the compound decreases the KD-r of the TNF superfamily member to the requisite receptor compared to the KD-r of the TNF superfamily member to its receptor in the absence of the compound, wherein:
a) the compound decreases the KD-r of the TNF superfamily member to the requisite receptor by at least 4 times compared to the KD-r of the TNF superfamily member to its receptor in the absence of the compound;
b) the KD-r value of the TNF superfamily member for binding to the requisite receptor in the presence of the compound is less than 600 pM.

### Claim 20 (depends on 19)

The method of claim 19, wherein the KD-r value of the TNF superfamily member for binding to the requisite receptor in the presence of the compound is less than 200 pM.

### Claim 21 (depends on 1)

The method of claim 1, wherein said compound has an IC50 value of 500 nM or less.

### Claim 22 (depends on 1)

The method of claim 1, wherein the TNF superfamily member is TNFα and the receptor is the TNF receptor.

### Claim at position 22

23-40. (canceled)
